Floatz logo

axp107-11

Amyloid Cardiomyopathy

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Amyloid Cardiomyopathy cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
fx-1006a
Pfizer
Phase 4BB
Empagliflozin
Columbia University
Phase 4BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

axp107-11 is also rated in:

prostate adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
pediatric lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
childhood malignant neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →